First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Sanofi

    SNY · 2 developments mapped · last assessed 2026-09-06

    Market Ontology has mapped 2 macro, policy, and market developments to Sanofi since 2026-09-06. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for SNY yet, so no modelled value is shown. The SNY valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run SNY on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for SNY. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics

      Direct increase in market opportunity for Dupixent (co-developed with Regeneron), a leading biologic in atopic dermatitis. Increased sales volume and potential for price stability/growth.

      · Moves revenue growth rate, market share assumptions, terminal growth rate

    What changed, by assumption

    Revenue growth rate
    • 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
    • 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-06Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-06Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-06RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics DemandBullish1-5y0.70
    2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsBullish3-12m0.80